Mankind Pharma Ltd

NSE:MANKINDHealthcareNSE:CNX200NSE:CNX500

——At close · Market cap — · Next earnings Mon 26 Oct

MANKIND · Income statement · TradingHolo

INR billions	FY2021	FY2022	FY2023	FY2024	FY2025	FY2026	TTM	YoY
Revenue	62.1	77.8	87.5	102.6	122.1	142.8	147.4	+3.2%
Cost of revenue	18.2	24.7	29.6	32.6	35.7	81.2	83.0	+2.2%
Gross profit	43.9	53.1	57.9	70.0	86.4	61.6	64.3	+4.5%
Research & development	0.0	0.0	0.0	0.0	0.0	0.0	—	—
Selling, general & administrative	18.2	20.9	23.1	28.8	34.7	34.2	—	—
Selling & marketing	0.0	0.0	0.0	0.0	0.0	0.0	—	—
Operating expenses	27.8	34.3	41.5	47.6	61.2	34.2	35.0	+2.2%
Operating income	16.1	18.8	16.4	22.4	25.2	27.3	29.3	+7.4%
Interest expense	0.2	0.2	0.4	0.3	4.1	6.4	5.8	−9.5%
Interest income	0.4	0.1	0.1	0.4	0.7	0.0	0.0	—
Other income / expense	0.9	0.9	0.3	1.6	0.0	(4.0)	—	—
Pre-tax income	16.9	19.7	16.7	24.0	25.2	23.3	25.5	+9.3%
Income tax	4.0	5.2	3.6	4.6	5.1	3.9	4.9	+25.2%
Net income	12.7	14.3	12.8	19.1	19.9	19.1	20.4	+6.8%
Discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0	—	—
Other net income adjustments	0.0	0.0	0.0	0.0	0.0	0.0	—	—
EPS, basic (per share)	31.59	35.78	32.00	47.75	49.17	46.35	49.48	+6.8%
EPS, diluted (per share)	31.59	35.78	32.00	47.68	49.09	46.28	49.42	+6.8%
EBITDA	18.3	22.0	20.4	28.0	35.6	38.6	38.3	−0.8%
Depreciation & amortization	1.2	1.7	3.3	3.8	6.2	8.9	—	—
Weighted average shares (shares)	400,588,000	400,588,000	400,588,440	400,588,000	404,667,000	412,714,000	—	—
Weighted average diluted shares (shares)	400,588,000	400,588,000	400,591,307	401,167,000	404,667,000	413,338,000	—	—
Gross margin	70.6%	68.3%	66.1%	68.3%	70.8%	43.1%	43.7%	+0.5 pts
Operating margin	25.9%	24.2%	18.8%	21.8%	20.6%	19.1%	19.9%	+0.8 pts
Net margin	20.4%	18.4%	14.7%	18.6%	16.3%	13.4%	13.9%	+0.5 pts

INR billionsUpdated Thu 30 Jul ·

ⓘ

Amounts are shown in the stated units; per-share amounts and shares are unscaled. Negative amounts are in brackets.

TTM ends 2026-06-30 and uses four consecutive reported quarters.